Arrowhead has already gained 21% in 2019, thanks to activity for two new drug candidates. ARO-APOC3 is an experimental triglyceride treatment waiting for a green light from the Food and Drug Administration to begin its first clinical trial. The company also began dosing healthy volunteers with ARO-ANG3, another experimental treatment for abnormal triglycerides and cholesterol levels. With Johnson & Johnson footing the bills for ARO-HBV's development from now on, Arrowhead can advance its growing pipeline without burning through its cash cushion too fast. The company finished September with $76.5 million in cash and investments after losing $54.5 million during the fiscal year ended in September. #stocks #success #bitcoin #stockmarket #nasdaq #forex #trader #millions #billions #cryptocurrency #network #daytrader #business #entrepreneur #motivation #quote #amazon #wealth #inspiration #blockchain #investing #money #lifestyle #daytrading #economy #trump #education #finance #wallstreet #nyse @stocksharks stocksharks Stock Sharks 📈

  • stocksharks

    @stocksharks

    2 months ago
  • Arrowhead has already gained 21% in 2019, thanks to activity for two new drug candidates. ARO-APOC3 is an experimental triglyceride treatment waiting for a green light from the Food and Drug Administration to begin its first clinical trial. The company also began dosing healthy volunteers with ARO-ANG3, another experimental treatment for abnormal triglycerides and cholesterol levels. With Johnson & Johnson footing the bills for ARO-HBV's development from now on, Arrowhead can advance its growing pipeline without burning through its cash cushion too fast. The company finished September with $76.5 million in cash and investments after losing $54.5 million during the fiscal year ended in September. #stocks #success #bitcoin #stockmarket #nasdaq #forex #trader #millions #billions #cryptocurrency #network #daytrader #business #entrepreneur #motivation #quote #amazon #wealth #inspiration #blockchain #investing #money #lifestyle #daytrading #economy #trump #education #finance #wallstreet #nyse
    Stock Sharks 📈 Arrowhead has already gained 21% in 2019, thanks to activity for two new drug candidates. ARO-APOC3 is an experimental triglyceride treatment waiting for a green light from the Food and Drug Administration to begin its first clinical trial. The company also began dosing healthy volunteers with ARO-ANG3, another experimental treatment for abnormal triglycerides and cholesterol levels.

With Johnson & Johnson footing the bills for ARO-HBV's development from now on, Arrowhead can advance its growing pipeline without burning through its cash cushion too fast. The company finished September with $76.5 million in cash and investments after losing $54.5 million during the fiscal year ended in September.

#stocks #success #bitcoin #stockmarket #nasdaq #forex #trader #millions #billions #cryptocurrency #network #daytrader #business #entrepreneur #motivation #quote #amazon #wealth #inspiration #blockchain #investing #money #lifestyle #daytrading #economy #trump #education #finance #wallstreet #nyse

    Arrowhead has already gained 21% in 2019, thanks to activity for two new drug candidates. ARO-APOC3 is an experimental triglyceride treatment waiting for a green light from the Food and Drug Administration to begin its first clinical trial. The company also began dosing healthy volunteers with ARO-ANG3, another experimental treatment for abnormal triglycerides and cholesterol levels.

    With Johnson & Johnson footing the bills for ARO-HBV's development from now on, Arrowhead can advance its growing pipeline without burning through its cash cushion too fast. The company finished September with $76.5 million in cash and investments after losing $54.5 million during the fiscal year ended in September.

    #stocks #success #bitcoin #stockmarket #nasdaq #forex #trader #millions #billions #cryptocurrency #network #daytrader #business #entrepreneur #motivation #quote #amazon #wealth #inspiration #blockchain #investing #money #lifestyle #daytrading #economy #trump #education #finance #wallstreet #nyse

  • 446 4
  • Save Image Other Pictures